Noematrix raises Series B for its embodied-AI 'brain'
What's the deal? Noematrix, a Chinese embodied intelligence startup, has closed a Series B round worth several hundred million yuan. Wuxi Data Group led the round, with participation from Shanghai Jiao Tong University AI Future Fund, Shanghai Chuangzhizhi Technology Co., and Yicun CapitalDealroom has a profile for this one. Try Dealroom →.
Founded in November 2023, Noematrix builds what it calls an "embodied brain" — a foundation model that gives robots the ability to perceive, plan, and act in real physical environments. Its prior backers include Sequoia China, Alibaba , Prosperity7 Ventures, C Capital, and Sea Limited.
Why now? The embodied AI sector is shifting from demo-ready tricks to deployment-ready reliability. The new benchmark isn't whether a robot can grab an object on a lab bench — it's whether it can do so thousands of times in a messy, ever-changing real-world setting.
Noematrix has found an early proving ground in pharmacies. Its robots handle online order fulfilment inside retail pharmacy stores, picking from thousands of SKUs without requiring any shelf or layout modifications. The system fits within 2.5 square metres and plugs into a store's existing order management software.
The company says it has reached commercial delivery stage with multiple major pharmacy chains, with orders already at the thousand-unit level.
What could go wrong? Edge cases remain the hardest challenge. A tube of erythromycin ointment too small to grip reliably, a thermometer hung on a peg instead of boxed — these low-probability situations are constant in live retail. Noematrix acknowledges that solving them demands massive volumes of real-world data, not algorithmic breakthroughs.
Scaling across cities and store formats will test whether the system's generalisation holds. The company currently operates in first- and second-tier cities including Guangzhou, Shenyang, and Nantong.
The signal: Noematrix, classified as a breakout-stage company by Dealroom despite being barely 18 months old, is riding a wave of capital into Chinese embodied AI — but its investor mix here is notable. A corporate backer (Wuxi Data Group) and university-linked funds are replacing the pure venture names (Sequoia China, Alibaba, Sea Limited) that powered earlier rounds, suggesting the company is now optimising for data access and research pipelines over brand-name VC endorsement. The thousand-unit order pipeline and an 18-to-24-month payback pitch give it a commercial traction story that most embodied AI peers, still stuck in pilot mode, cannot yet match.
